✦ LIBER ✦

Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes

✍ Scribed by Pellegrino Musto; Francesco Lanza; Enrico Balleari; Alberto Grossi; Antonietta Falcone; Grazia Sanpaolo; Carlo Bodenizza; Potito Rosario Scalzulli; Antonio La Sala; Diana Campioni; Riccardo Ghio; Nicola Cascavilla; Angelo Michele Carella

Book ID: 108672956
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 112 KB
Volume: 128
Category: Article
ISSN: 0007-1048
DOI: 10.1111/j.1365-2141.2004.05288.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose darbepoetin alpha in the treat

High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study

✍ L. Mannone; C. Gardin; M. C. Quarre; J. F. Bernard; D. Vassilieff; L. Ades; S. P 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Darbepoetin alfa for the treatment of an

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes

✍ Sylvia T. Singer; Elliott P. Vichinsky; Nancy Sweeters; Eliezer Rachmilewitz 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB

Darbepoetin α for the treatment of anemi

Darbepoetin α for the treatment of anemia in patients with myelodysplastic syndromes

✍ Pilar Giraldo; Benet Nomdedeu; Javier Loscertales; Carmen Requena; Raquel de Paz 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 295 KB

A Decision analysis to determine the app

A Decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes

✍ Mikkael A. Sekeres; Alex Z. Fu; Jaroslaw P. Maciejewski; Ali-Reza Golshayan; Mat 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 247 KB 👁 1 views

## Abstract ## BACKGROUND. The myelodysplastic syndromes (MDS) are divided into low‐risk and high‐risk diseases. Predictive models for response to growth factors (GF) have been developed based on red blood cell transfusion needs and erythropoietin levels. For low‐risk MDS the optimal initial thera

Phase 2, single-arm trial to evaluate th

Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes

✍ Janice Gabrilove; Ronald Paquette; Roger M. Lyons; Chaudhry Mushtaq; Mikkael A. 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB

Treatment of anemia in low-risk myelodys

Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response

✍ N. Viniou; E. Terpos; A. Galanopoulos; E. Kritikou-Griva; S. Akel; E. Michalis; 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 36 KB